<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514277</url>
  </required_header>
  <id_info>
    <org_study_id>VirtuaHealthExparel</org_study_id>
    <nct_id>NCT03514277</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Compare Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Pain Relief</brief_title>
  <official_title>Combined Administration of Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Analgesia in Posterior Lumbar Spine Surgery - A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virtua Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virtua Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information about how patients feel when doctors&#xD;
      manage their pain after lumbar spine surgery using a combination of EXPAREL® and bupivacaine&#xD;
      injected into the lumbar spine at the end of surgery, compared to the patients that doctors&#xD;
      use only EXPAREL® or bupivacaine to manage their pain. This information will help doctors&#xD;
      determine which approach works best for patients who will receive surgery in their lumbar&#xD;
      spine in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI decision to close study early&#xD;
  </why_stopped>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Postoperative Pain Score</measure>
    <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
    <description>Wong-Baker pain faces scale of 0-no pain, to 10-extreme pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Consumption of Opioids During Hospital Stay</measure>
    <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
    <description>All opioid analgesics will be converted into oral mg morphine equivalent to determine the total dose of opioids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Achieve Physical Therapy Discharge</measure>
    <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
    <description>Mean time to achieve physical therapy discharge criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Opioid Related Adverse Events</measure>
    <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
    <description>Number of Participants with Opioid Related Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Lumbosacral Radiculopathy</condition>
  <condition>Lumbar Disc Degeneration</condition>
  <condition>Lumbar Disc Herniation</condition>
  <condition>Stenosis</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spondylolysis</condition>
  <condition>Deformity of Spine</condition>
  <arm_group>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Local infiltration of Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Local infiltration of Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
    <arm_group_label>Local infiltration of Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>30 mL bupivacaine 0.5% w/v solution</description>
    <arm_group_label>Local infiltration of Bupivacaine</arm_group_label>
    <arm_group_label>Local infiltration of EXPAREL and Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or older;&#xD;
&#xD;
          2. Primary indication is low back pain, lumbosacral radiculopathy, lumbar disc&#xD;
             degeneration, lumbar disc herniation, stenosis, spondylolisthesis, spondylolysis, or&#xD;
             deformity requiring surgical intervention;&#xD;
&#xD;
          3. Scheduled to undergo primary, 1 or 2 level, posterior lumbar laminectomy with or&#xD;
             without fusion, discectomy with fusion, or fusion at Virtua Memorial Hospital;&#xD;
&#xD;
          4. Willing to provide informed consent, participate in study, and comply with study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity or allergy to local anesthetics;&#xD;
&#xD;
          2. Pregnant or contemplating pregnancy prior to surgery;&#xD;
&#xD;
          3. Previous surgery in lumbar spine (i.e. other than microdiscectomy);&#xD;
&#xD;
          4. Prior treatment for alcohol, recreational drug, or opioid abuse;&#xD;
&#xD;
          5. Serious spinal conditions (e.g. spinal cord compression, cauda equina syndrome, spinal&#xD;
             infection, spinal tumor, spinal fracture, inflammatory or systemic spinal arthritis);&#xD;
&#xD;
          6. Surgery involving more than 2 vertebral levels;&#xD;
&#xD;
          7. Worker's compensation or personal injury related to lumbar spine (treatment outcomes&#xD;
             may be affected by patient's personal interests [21]; could also run into potential&#xD;
             issues with reimbursement).&#xD;
&#xD;
          8. Lactating women&#xD;
&#xD;
          9. Patients with end stage liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Greenleaf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princpal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virtua Memorial Hospital</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <results_first_submitted>November 6, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolysis</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publish research findings in relevant peer-reviewed journal</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03514277/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Local Infiltration of EXPAREL and Bupivacaine</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
        <group group_id="P2">
          <title>Local Infiltration of Exparel</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
        </group>
        <group group_id="P3">
          <title>Local Infiltration of Bupivacaine</title>
          <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Local Infiltration of EXPAREL and Bupivacaine</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
        <group group_id="B2">
          <title>Local Infiltration of Exparel</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
        </group>
        <group group_id="B3">
          <title>Local Infiltration of Bupivacaine</title>
          <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" lower_limit="52" upper_limit="77"/>
                    <measurement group_id="B2" value="72.3" lower_limit="66" upper_limit="80"/>
                    <measurement group_id="B3" value="67.3" lower_limit="54" upper_limit="74"/>
                    <measurement group_id="B4" value="68.6" lower_limit="52" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Postoperative Pain Score</title>
        <description>Wong-Baker pain faces scale of 0-no pain, to 10-extreme pain</description>
        <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
        <population>Data is not collected for one patient in the Local infiltration of EXPAREL and Bupivacaine group</population>
        <group_list>
          <group group_id="O1">
            <title>Local Infiltration of EXPAREL and Bupivacaine</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
          <group group_id="O2">
            <title>Local Infiltration of Exparel</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
          </group>
          <group group_id="O3">
            <title>Local Infiltration of Bupivacaine</title>
            <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Postoperative Pain Score</title>
          <description>Wong-Baker pain faces scale of 0-no pain, to 10-extreme pain</description>
          <population>Data is not collected for one patient in the Local infiltration of EXPAREL and Bupivacaine group</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.0" upper_limit="7.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.1" upper_limit="5.6"/>
                    <measurement group_id="O3" value="5.6" lower_limit="4.4" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Consumption of Opioids During Hospital Stay</title>
        <description>All opioid analgesics will be converted into oral mg morphine equivalent to determine the total dose of opioids</description>
        <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
        <population>Data is not collected for one patient in the Local infiltration of EXPAREL and Bupivacaine group</population>
        <group_list>
          <group group_id="O1">
            <title>Local Infiltration of EXPAREL and Bupivacaine</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
          <group group_id="O2">
            <title>Local Infiltration of Exparel</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
          </group>
          <group group_id="O3">
            <title>Local Infiltration of Bupivacaine</title>
            <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
        </group_list>
        <measure>
          <title>Total Consumption of Opioids During Hospital Stay</title>
          <description>All opioid analgesics will be converted into oral mg morphine equivalent to determine the total dose of opioids</description>
          <population>Data is not collected for one patient in the Local infiltration of EXPAREL and Bupivacaine group</population>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.1" lower_limit="0" upper_limit="300"/>
                    <measurement group_id="O2" value="87.3" lower_limit="4" upper_limit="202.5"/>
                    <measurement group_id="O3" value="46.1" lower_limit="13.5" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to Achieve Physical Therapy Discharge</title>
        <description>Mean time to achieve physical therapy discharge criteria</description>
        <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
        <population>This data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Local Infiltration of EXPAREL and Bupivacaine</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
          <group group_id="O2">
            <title>Local Infiltration of Exparel</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
          </group>
          <group group_id="O3">
            <title>Local Infiltration of Bupivacaine</title>
            <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Achieve Physical Therapy Discharge</title>
          <description>Mean time to achieve physical therapy discharge criteria</description>
          <population>This data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Opioid Related Adverse Events</title>
        <description>Number of Participants with Opioid Related Adverse Events</description>
        <time_frame>last day of hospitalization, average of 3 days in hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Local Infiltration of EXPAREL and Bupivacaine</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
          <group group_id="O2">
            <title>Local Infiltration of Exparel</title>
            <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
          </group>
          <group group_id="O3">
            <title>Local Infiltration of Bupivacaine</title>
            <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Opioid Related Adverse Events</title>
          <description>Number of Participants with Opioid Related Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of patient's hospital stay, an average of three days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Local Infiltration of EXPAREL and Bupivacaine</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL&#xD;
Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
        <group group_id="E2">
          <title>Local Infiltration of Exparel</title>
          <description>Exparel: 1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL</description>
        </group>
        <group group_id="E3">
          <title>Local Infiltration of Bupivacaine</title>
          <description>Bupivacaine: 30 mL bupivacaine 0.5% w/v solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constitpation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Unsteadiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Greenleaf</name_or_title>
      <organization>Reconstructive Orthopedics</organization>
      <phone>609-267-9400</phone>
      <email>bob.greenleaf1@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

